Skip to main content

Table 1 Baseline characteristics

From: Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study

Characteristics n = 38
Age (years) 53 (34-77)
Male 33 (86.8)
Etiology
 HBV 29 (76.3)
 HCV 1 (4.8)
 NBNC 8 (18.9)
Liver cirrhosis 30 (78.9)
Child-Pugh class (A/B)
 Class A 32 (84.2)
 Class B 6 (15.8)
ECOG performance status  
 Grade 0 5 (13.2)
 Grade 1 33 (86.8)
Vascular invasion
 Main portal trunk invasion 16 (42.1)
 Left of right lobar portal vein invasion 15 (39.5)
 Segmental portal vein invasion 5 (13.1)
 Hepatic vein invasion 2 (5.3)
BCLC stage
 Advanced (C) 38 (100)
AJCC stage
 IIIB 20 (52.6)
 IIIC 1 (2.6)
 IVA 15 (39.5)
 IVB 2 (5.3)
Tumor size (cm) 11.6 (3.5-21.1)
AFP (ng/mL) 1573.0 (2.0-54,000)
DCP (mAU/mL) 4378.0 (18.0-75,000)
Radiation dose (cGy) 4500 (3060-6250)
Round of HAIC 3.5 (0-18)
TACE 19 (50.0)
 For local residual tumor 6 (31.6)
 For newly recurring tumor 13 (68.4)
  1. Variables are expressed as medians (range) or n (%)
  2. HBV Hepatitis B virus, HCV Hepatitis C virus, NBNC Non-B and non-C, ECOG The Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, AJCC The American Joint Committee on Cancer, AFP α-fetoprotein, DCP Des-gamma carboxyprothrombin, HAIC Hepatic arterial infusional chemotherapy, TACE Transarterial chemoembolization